Evidence mapPaperPMID 39448212Full record

ArticleBMJ open2024

Experiences across a genetic screening and testing programme pathway: a qualitative study of mammogram patient perspectives.

Claire Devine, Kate R Emery, Kimberly K Childers, Sandra Brown, Ora Gordon, Sarah E Roth

Abstract read
In one paragraph

Article in BMJ open, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Contextual factors of implementing APOL1 genetic testing into living kidney donor clinical evaluation.Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Claire DevineCenter for Outcomes Research and Education (CORE), Providence Health and Services Oregon, Portland, Oregon, USA.
Kate R EmeryProvidence Genomics, Renton, Washington, USA.
Kimberly K ChildersProvidence Clinical Genetics and Genomics Program, Los Angeles Region, Providence Genomics, Los Angeles, California, USA.
Sandra BrownProvidence Clinical Genetics and Genomics Program, Orange County High Desert Region, Providence Genomics, Orange, California, USA.
Ora GordonProvidence Clinical Genetics and Genomics Programs, Southern California, Providence Genomics, Torrance, California, USA.
Sarah E RothCenter for Outcomes Research and Education (CORE), Providence Health and Services Oregon, Portland, Oregon, USA Sarah.Roth@providence.org.ORCID http://orcid.org/0000-0002-6110-3738

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPopulation-based genetic screening and testing programmes have substantial potential to improve cancer-related outcomes through early detection and cancer prevention. Yet, genetic testing for cancer risk remains largely underused. This study aimed to describe barriers and facilitators to patient engagement at each stage of a California-based genetic screening programme, from completing the electronic screener to receiving the test and to identify potential improvements that could support precision medicine-based approaches to patient care.

methodsWe conducted 26 semistructured interviews among programme participants who did not complete the screener (n=9), those who did not receive the recommended test (n=7) and those who received a genetic test (n=10). Interviewees were selected from patients who recently received a mammogram through one of the participating Southern California clinics. Interviews were transcribed and coded using Atlas.ti. The study used a qualitative descriptive approach to identify similar and contrasting themes among the participant groups.

resultsThis study found that barriers and facilitators to engagement were largely the same regardless of how far participants had moved through the process towards getting a genetic test. We identified four overarching themes: participants wanted clear communication of personal benefits at each stage; participants needed additional information and knowledge to navigate genetic screening and testing; a trusted provider could be instrumental in participants following a recommendation; and repetition and timing strongly impacted participants' likelihood to engage.

conclusionsProviding education about the benefits of genetic screening and testing to patients and their families, as well as clear communication about what each step entails may help patients engage with similar programmes. Strategies aimed at increasing coordination among a patient's healthcare team can also help ensure information reaches patients in multiple ways, from multiple providers, to increase the likelihood that recommendations for testing come from trusted sources, which supports the uptake of genetic testing.

Indexed as

Breast NeoplasmsEarly Detection of CancerGenetic TestingMammographyQualitative ResearchAdultAgedCaliforniaFemaleHumansInterviews as TopicMiddle AgedPatient Acceptance of Health CarePatient Participationcancer geneticsmass screeningpatient satisfactionquality improvement

Identifiers

PMID39448212
PMCPMC11499760

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.